AbbVie (ABBV-1.53%) and Pfizer (PFE-1.88%) stand out as two of the best in the industry. So far this year, Pfizer has been the bigger winner in terms of stock performance .

We compare AbbVie and Pfizer and determine which is a better high-yield pick for investors. Click here to know the results.

Pfizer's Coming for AbbVie's Market Share. ... (now that Humira is seeing competition from generics as a result of going over the patent cliff in the U.S. this year).

AbbVie ABBV has been expanding its oncology portfolio over the past few years. While the company was originally focused on two blood-cancer drugs — Imbruvica and Venclexta — it has since built a ...

Pfizer's net income was $7,864 million in Q2 2022, up 131.8% QoQ. AbbVie's net income was $924 million in Q2 2022, up 20.6% year-on-year. It is unlikely that the Inflation Reduction Act will have ...

If you're looking for juicy dividend yields, you might want to check out big pharmaceutical stocks. AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE) stand out as two of the best in the industry.

AbbVie and Pfizer currently offer two of the highest dividend payouts among major drugmakers, with respective yields of 3.8% and 3.7%, according to S&P Global Market Intelligence .

In terms of its financial outlay, AbbVie is buying ImmunoGen for just over $10 billion in cash, so right off the bat it's clear that the scale of its commitment isn't as large as Pfizer's.

AbbVie has placed a high price on that potential, coughing up $700 million for a phase 1 candidate and offering up to $1.225 ...

By Christy Santhosh (Reuters) -AbbVie said on Monday it would acquire privately held cell therapy developer Capstan Therapeutics in a deal worth up to $2.1 billion, expanding its product pipeline with ...

In terms of its financial outlay, AbbVie is buying ImmunoGen for just over $10 billion in cash, so right off the bat it's clear that the scale of its commitment isn't as large as Pfizer's.